The study aims to evaluate the effectiveness and safety of donidalorsen as a long-term prophylaxis for hereditary angioedema.
Patients switched from other long-term prophylactic treatments to donidalorsen.
Assessment of HAE attack rates, quality of life, and overall disease control over one year.
Donidalorsen was well tolerated among patients.
Significant reduction in long-term HAE attack rates was observed.
Improvement in quality of life and disease management reported.
Abstract
In patients who switched from another LTP, donidalorsen was well tolerated and improved long-term HAE attack rates, quality of life, and disease control.